Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.
about
AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progressionMaspin: the new frontierCharacterization of nuclear import of the domain-specific androgen receptor in association with the importin alpha/beta and Ran-guanosine 5'-triphosphate systemsThe neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor.Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cellsThe NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptorThe impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activityA novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude miceCharacterization of tumor differentiation factor (TDF) and its receptor (TDF-R).The hedgehog/Gli signaling paradigm in prostate cancerThe 26S proteasome complex: an attractive target for cancer therapyCelastrol Induces Autophagy by Targeting AR/miR-101 in Prostate Cancer Cells.Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation.Androgen receptor and prostate cancer.Methylation-induced silencing of maspin contributes to the proliferation of human glioma cellsMolecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.Pleiotropic functional properties of androgen receptor mutants in prostate cancer.UBAP2 negatively regulates the invasion of hepatocellular carcinoma cell by ubiquitinating and degradating Annexin A2.HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.Insulin-like growth factor 1 stimulation of androgen receptor activity requires β(1A) integrins.Bisbibenzyls, novel proteasome inhibitors, suppress androgen receptor transcriptional activity and expression accompanied by activation of autophagy in prostate cancer LNCaP cells.Disodium pentaborate decahydrate (DPD) induced apoptosis by decreasing hTERT enzyme activity and disrupting F-actin organization of prostate cancer cells.Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression.Expression, regulation and function of the ISGylation system in prostate cancer.Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cellsFluoride Alters Klk4 Expression in Maturation Ameloblasts through Androgen and Progesterone Receptor Signaling.[How should hormone therapy for castration-resistant prostate cancer be continued?]
P2860
Q21203668-20D64048-062B-4897-A63D-C4C4DB1DB8D5Q24635935-FCFFD666-8213-48C4-9592-392D16705DCBQ24653761-C220E3C7-4119-48CD-B579-57E27AF47F12Q30434799-D05A3711-2FCC-4564-A754-7007C375B650Q30500293-29F459FA-E1B0-490F-8166-3CEB5BB6CE5AQ33688960-C23D8DDA-F334-4111-BB11-0E51DB43F5C5Q34097585-EBA0B665-9A28-4E6B-BC4C-E56F5100205EQ34189517-70B69F48-FF48-4B7F-8DC1-9D48217766C9Q34196562-7FCD6F9E-BE0F-4941-8687-E080B3AF77EBQ34449941-26287D0B-5D2B-4950-8197-4F2533E016D3Q35109835-897D5B76-8ECC-4F54-A1E2-0433950B8F9EQ35624079-45544FC0-53A6-404F-9B07-69DF4D450201Q35810293-4008C473-9543-42F0-9052-53A4799793D3Q35869909-F3807F3D-00BE-4BBE-B60B-3AAC25B644E5Q36047094-7F183A5E-288F-42E8-865F-508683CA8932Q36734752-90C9EBCA-9F7D-480C-9252-395AA57657E4Q36983836-174882D3-DEAA-43C9-B7B0-9A7A389E13ACQ37010879-1B9D7865-22B1-4A9B-8302-CC221B653949Q37272639-B5B73FCF-3BD9-42FB-BBDE-42A881A0E760Q37362811-BC9B346F-1422-4B79-9ADE-E0EF7D243B4DQ37484581-050FCB69-B09A-45CB-987A-E4519C4D0012Q38739702-1987FB10-60E9-4001-B4EF-E514FAF473BCQ38870314-0F8159AF-5593-4F1D-82CE-D4343C231541Q39079692-36B67AD6-F1F7-4415-B853-4D4BE3DE0E6CQ39427379-841B1A4E-2720-4F7B-A560-110F42D91CFEQ39791652-4FC46DA1-6854-4A37-8733-74A281E9F7C9Q39853440-2BE2F19D-9DBD-446E-8873-717A94667B9FQ39947179-837D2228-0500-4E55-ACA1-1055FC6F2649Q47283847-DEC35D92-DC92-4E75-9039-2BF122F05A5CQ57135372-F35AD8E2-3CD6-4BA0-831C-83E09CCBC3B3
P2860
Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Regulatory processes affecting ...... ne-refractory prostate cancer.
@ast
Regulatory processes affecting ...... ne-refractory prostate cancer.
@en
type
label
Regulatory processes affecting ...... ne-refractory prostate cancer.
@ast
Regulatory processes affecting ...... ne-refractory prostate cancer.
@en
prefLabel
Regulatory processes affecting ...... ne-refractory prostate cancer.
@ast
Regulatory processes affecting ...... ne-refractory prostate cancer.
@en
P2093
P2860
P356
P1476
Regulatory processes affecting ...... ne-refractory prostate cancer.
@en
P2093
Evelyn R Barrack
Fazlul H Sarkar
G Prem Veer Reddy
Mani Menon
Q Ping Dou
Ronald Pelley
Shijie Sheng
P2860
P304
P356
10.1002/JCB.20927
P577
2006-08-01T00:00:00Z